Preprint alert 🚨 Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐 Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells biorxiv.org/content/10.110… 🧵👇

Have you ever wanted to design protein binders with ease? Today we present 𝑩𝒊𝒏𝒅𝑪𝒓𝒂𝒇𝒕, a user-friendly and open-source pipeline that allows to anyone to create protein binders de novo with high experimental success rates. Bruno Correia Sergey Ovchinnikov biorxiv.org/content/10.110…

Whenever I see “we raised $200m for our series A” I translate it as “We will be very inefficient”. The sheer number of ways we found to save time & money that “serious biotech companies” wouldn’t do - from cloning plasmids in China to finding “underground” biologists who charge

Thrilled to share our back-to-back two Nature nature papers on the unexpected role of type 2 immunity against cancer. We found that interleukin 4 (Fc–IL-4), a type 2 cytokine, reinvigorates exhausted T cells to potentiate anticancer immunotherapy w/ Yugang GUO Rong Fan(1/11)

What if you could find out the history of signaling activity in each cell with a single round of imaging? Wouldn't that be incredible? Well, we thought so too. And that's what we set out to achieve with INSCRIBE in our new preprint. Let’s dive in! 🚀🔬 biorxiv.org/content/10.110…

Check out our latest research by Mohsen Naghipourfar and others in our team on building language models of coding sequence. In this preprint, we introduce cdsFM, a suite of codon-resolution language models!👇 biorxiv.org/content/10.110…

Today, I'm excited to present the second big chunk of my Ph.D. work. We are building a thorough assessment of the burgeoning field of gene expression forecasting. Something is deeply wrong.🧵 - Preprint: biorxiv.org/content/10.110… - Code: github.com/ekernf01/pertu…

We have a new preprint (biorxiv.org/content/10.110…)! I’m excited to introduce our latest deep learning model, Decima. More in this thread:🧵 1/14

Avantika Lal Great to see this Avantika! Want to swing by and present it?

Excited to open up work on improving the power of Deep Mutational Scanning and applying it to drug discovery. I’ll comment on the preprint itself, which is work from a few years ago on DMS of MC4R, as well as talk about how this has evolved Octant Bio over time. 1/🧵

I love this diagram of the flightosome by Arjun Raj How do we improve biological models ?

This new R package is wild. It's called ggalign. Here's what it can do:

In the latest issue! Neoself-antigens are the primary target for autoreactive T cells in human lupus dlvr.it/TFXvPl

Our new study published today nature uncovers that Transgelin 2 preserves T cell lipid metabolism and anti-tumor activity. Transgelin 2 is silenced in dysfunctional TILs, and restoring its expression enhances CAR-T cell therapy in #OvarianCancer 👇nature.com/articles/s4158…

Nature research paper: Machine-guided design of cell-type-targeting cis-regulatory elements go.nature.com/3A0nksF

CENCAT; an immunometabolic profiling tool that blends the SCENITH. Single Cell Metabolism approach with BONCAT click chemistry to measure metabolic dependencies of cell subsets Cell Reports Methods paper online now ➡️ cell.com/cell-reports-m…

1/ We Octant Bio are excited to help start the OpenADMET consortium, catalyzed by this grant from ARPA-H! We will build open datasets, competitions and ultimately foundation models for small molecule PK and safety properties. In the 🧵👇, I'll describe the problem & our approach